ARWR vs RNA

Arrowhead Pharmaceuticals continues to demonstrate strong 10x growth potential within 3-5 years. The Q1 2026 financials (fiscal quarter ended Dec 31, 2025) showcased a significant revenue beat of $264.0M, driven by the successful commercial launch of Redemplo, and a positive net margin of 18.54%. Critically, the recently announced two-year efficacy data for plozasiran, showing an 83% triglyceride ...

Avidity Biosciences (RNA) continues to demonstrate strong 10x growth potential, sustained by its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. The lead asset, AOC 1001 for Myotonic Dystrophy Type 1 (DM1), remains critically important, with the path to potential regulatory filing in late 2026/early 2027 still intact. This timeline, coupled with ongoing clinical progress for AOC 102...